| __timestamp | Taro Pharmaceutical Industries Ltd. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 55430000 | 45967000 |
| Thursday, January 1, 2015 | 65510000 | 114737000 |
| Friday, January 1, 2016 | 71160000 | 183204000 |
| Sunday, January 1, 2017 | 70644000 | 231644000 |
| Monday, January 1, 2018 | 70418000 | 293998000 |
| Tuesday, January 1, 2019 | 63238000 | 357355000 |
| Wednesday, January 1, 2020 | 59777000 | 412084000 |
| Friday, January 1, 2021 | 60152000 | 497153000 |
| Saturday, January 1, 2022 | 54540000 | 705789000 |
| Sunday, January 1, 2023 | 52243000 | 648449000 |
| Monday, January 1, 2024 | 64536000 |
Unleashing the power of data
In the competitive landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. From 2014 to 2023, Ultragenyx Pharmaceutical Inc. has consistently outpaced Taro Pharmaceutical Industries Ltd. in R&D investment. Ultragenyx's R&D expenses surged by over 1,300% from 2014 to 2022, peaking in 2022 with a staggering 705 million dollars. In contrast, Taro's R&D spending remained relatively stable, with a modest 17% increase over the same period, reaching its highest in 2016. This disparity highlights Ultragenyx's aggressive pursuit of innovation, while Taro maintains a more conservative approach. The data for 2024 is incomplete, but the trend suggests Ultragenyx's continued dominance in R&D investment. As the pharmaceutical industry evolves, these spending patterns may significantly influence each company's market position and product pipeline.
R&D Spending Showdown: Merck & Co., Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Bio-Techne Corporation vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: Lantheus Holdings, Inc. vs Ultragenyx Pharmaceutical Inc.
Research and Development Expenses Breakdown: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Geron Corporation
Analyzing R&D Budgets: Ultragenyx Pharmaceutical Inc. vs MiMedx Group, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: Arrowhead Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Supernus Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.: Strategic Focus on R&D Spending
R&D Insights: How Taro Pharmaceutical Industries Ltd. and Novavax, Inc. Allocate Funds
Research and Development Expenses Breakdown: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.